BR vs ZYME · P/E 16, rev $6.89B vs rev $76.3M
Broadridge Financial Solutions Inc (BR) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
Broadridge Financial Solutions Inc (BR) is a information technology services company listed on US.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported BR revenue for 2025-06-30 was $6.89B. Net income was $839.5M. Revenue was up 5.9% from 2024-06-30 to 2025-06-30. BR currently screens at market cap $17.65B and trailing P/E 16.3.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
BR currently screens at market cap $17.65B and trailing P/E 16.3. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the BR and ZYME stock pages for the full models.
Not investment advice.